(Q53103655)

11 May 2018

title

Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. (English)

1 reference

11 May 2018

3

Patrick A Kupelian

1 reference

11 May 2018

author name string

Jay P Ciezki

series ordinal

1

1 reference

11 May 2018

Chandana A Reddy

series ordinal

2

1 reference

11 May 2018

Eric A Klein

series ordinal

4

1 reference

11 May 2018

language of work or name

English

0 references

publication date

1 August 2012

1 reference

11 May 2018

published in

Urology

1 reference

11 May 2018

volume

80

1 reference

11 May 2018

issue

2

1 reference

11 May 2018

page(s)

367-372

1 reference

11 May 2018

Screening and prostate-cancer mortality in a randomized European study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

How to read a paper. Statistics for the non-statistician. II: "Significant" relations and their pitfalls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Quality of life and satisfaction with outcome among prostate-cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.03.061

10.1016/J.UROLOGY.2012.03.061

7 January 2021

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

22857756

1 reference

11 May 2018